University of Oxford and OSI have both returned for a $95.4m series C round that also included GV and, through the conversion of a note, Eli Lilly.

Evox Therapeutics, a UK-based exosome drug spinout of University of Oxford, raised £69.2m ($95.4m) in a series C round yesterday featuring the institution and its patient capital fund Oxford Sciences Innovation (OSI). Redmile Group led the round and was joined by GV, a corporate venturing arm of internet technology group Alphabet, OrbiMed, Invus, Panacea Healthcare…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.